Références

1. De Jong PE, Gansevoort RT. Focus on microalbuminuria to improve cardiac and renal protection. Nephron Clin Pract 2009 ; 111 : c204–c211.

2. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002 ; 92 : 536-41.

3. Writing Group for the CKD Prognosis Consortium. Estimated glomerular filtration rate, albuminuria, and adverse outcomes. An individual-participant data meta-analysis. JAMA 2023 ; 330: 1266-77.

4. Haute Autorité de santé. Guide du parcours de soins – Maladie rénale chroniquede l’adulte (MRC). HAS, 2023 : www.has-sante.fr/jcms/p_3288950/fr/guide-du-parcours-de-soins-maladie-renale-chronique-de-l-adulte-mrc.

5. KDIGO 2023 clinical practiceguideline for the evaluation and management of chronic kidney disease. Kidney Int 2023 ;in press.

6. Matsushita K, Coresh J, Sang Y, et al. Kidney measures beyond traditional risk factors for cardiovascular prediction : A collaborative meta-analysis. Lancet Diabetes Endocrinol 2015 ; 3 : 514-25.

7. Fox CS, Matsushita K, Woodward Mark, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis. Lancet 2012 ; 380 : 1662-73.



8. Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeos-tasis and management of dyskalemia in kidney diseases : Conclusions from a kidney disease : Improving Global Outcomes (KDIGO) Controversies Conference. Kindney Int 2020 ; 97 : 42-61.